期刊
ANTIVIRAL RESEARCH
卷 99, 期 3, 页码 207-213出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2013.05.017
关键词
Ebola virus; Luciferase; Firefly; Reverse genetics; Antiviral screening; High-throughput screening
资金
- Intramural Research Program of the NIH, NIAID
- Grants-in-Aid for Scientific Research [25115501, 24658252] Funding Source: KAKEN
Ebola virus (EBOV) causes a severe hemorrhagic fever with case fatality rates of up to 90%, for which no antiviral therapies are available. Antiviral screening is hampered by the fact that development of cytopathic effect, the easiest means to detect infection with wild-type EBOV, is relatively slow. To overcome this problem we generated a recombinant EBOV carrying a luciferase reporter. Using this virus we show that EBOV entry is rapid, with viral protein expression detectable within 2 h after infection. Further, luminescence-based assays were developed to allow highly sensitive titer determination within 48 h. As a proof-of-concept for its utility in antiviral screening we used this virus to assess neutralizing antibodies and siRNAs, with significantly faster screening times than currently available wild-type or recombinant viruses. The availability of this recombinant virus will allow for more rapid and quantitative evaluation of antivirals against EBOV, as well as the study of details of the EBOV life cycle. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据